The protein C anticoagulant pathway is critical for controlling microvascular thrombosis and is initiated when thrombin binds to thrombomodulin (TM) on the surface of the endothelium. Protein C activation is augmented by an endothelial cell protein C receptor (EPCR). EPCR is shed from the vasculature by inflammatory mediators and thrombin. EPCR binds to activated neutrophils in a process that involves proteinase 3 and Mac-1 and appears to inhibit leukocyte extravasation. EPCR can undergo translocation from the plasma membrane to the nucleus where it re-directs gene expression. During translocation, EPCR can carry activated protein C (APC) to the nucleus, possibly accounting for the ability of APC to modulate inflammatory mediator responses in the endothelium. TNF-α and other inflammatory mediators can down-regulate EPCR and TM. Inhibition of protein C pathway function increases cytokine elaboration, endothelial cell injury and leukocyte extravasation in response to endotoxin and infusion of APC reverses these processes. In vitro, APC has been reported to inhibit TNF-α elaboration from monocytes and to block leukocyte adhesion to selectins. Since thrombin can elicit many inflammatory responses in microvascular endothelium, loss of control of microvascular thrombin generation due to impaired protein C pathway function probably contributes to microvascular dysfunction in sepsis.
References
1.
Walsh PNPlatelet-mediated trigger mechanisms in the contact phase of blood coagulation . Semin Thromb Hemost1987; 13: 86—94.
2.
Edgington TS , Mackman N., Brand K., Ruf W.The structural biology of expression and function of tissue factor. Thromb Haemost1991; 66: 67—79.
3.
Peter L., Giesen A., Rauch U. et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA1999; 96: 2311—2315.
4.
Drake TA, Morrissey JH, Edgington TSSelective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol1989; 134: 1087—1097.
5.
Sims PJ, Faioni EM, Wiedmer T., Shattil SJComplement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem1988; 263: 18205—18212.
6.
Bevers EM, Comfurius P., Zwaal Rfa.Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev1991; 5: 146—154.
7.
Alberio L., Safa O., Clemetson KJ, Esmon CT, Dale GLSurface expression and functional characterization of a-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin . Blood2000; 95: 1694—1702.
8.
Taylor Jr FB , Chang A., Esmon CT, D'Angelo A., Vigano-D'Angelo S., Blick KEProtein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J Clin Invest1987; 79: 918—925.
9.
Burstein SACytokines, platelet production and hemostasis. Platelets1997; 8: 93—104.
10.
Huang Z-F., Higuchi D., Lasky N., Broze Jr GJ. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood1997; 90: 944—951.
11.
Ishiguro K. , Kojima T., Kadomatsu K. et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest2000; 106: 873—878.
12.
Weiler-Guettler H., Christie PD, Beeler DL et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest1998; 101: 1983—1991.
13.
Jalbert LR, Rosen ED, Moons L. et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest1998; 102: 1481—1488.
14.
Marcum JA, McKenney JB, Rosenberg RDThe acceleration of thrombin—antithrombin complex formation in hindquarters via naturally occurring heparin-like molecules bound to the endothelium. J Clin Invest1984; 74: 341—350.
15.
Heyderman RS , Klein NJ, Shennan GI, Levin M.Reduction of the anticoagulant activity of glycosaminoglycans on the surface of the vascular endothelium by endotoxin and neutrophils: evaluation by an amidolytic assay. Thromb Res1992; 67: 677—685.
16.
Klein NJ, Shennan GI, Heyderman RS, Levin M.Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci1992; 102: 821—832.
17.
Broze Jr GJ , Girard TJ, Novotny WFRegulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry1990; 29: 7539—7546.
18.
Stearns-Kurosawa DJ, Kurosawa S., Mollica JS, Ferrell GL, Esmon CTThe endothelial cell protein C receptor augments protein C activation by the thrombin—thrombomodulin complex. Proc Natl Acad Sci USA1996; 93: 10212—10216.
19.
Laszik Z., Mitro A., Taylor Jr FB, Ferrell G., Esmon CTHuman protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation1997; 96: 3633—3640.
20.
Liaw Pcy, Neuenschwander PF, Smirnov MD, Esmon CTMechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem2000; 275: 5447—5452.
21.
Shu F., Kobayashi H., Fukudome K., Tsuneyoshi N., Kimoto M., Terao T.Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. FEBS Lett2000; 477: 208—212.
22.
Riewald M., Petrovan RJ, Donner A., Mueller BM, Ruf W.Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science2002; 296: 1880—1882.
23.
Grey S., Hau H., Salem HH, Hancock WWSelective effects of protein C on activation of human monocytes by lipopolysaccharide, interferon-gamma, or PMA: modulation of effects on CD11b and CD14 but not CD25 or CD54 induction. Transplant Proc1993 ; 25: 2913—2914.
24.
Joyce DE, Gelbert L., Ciaccia A., DeHoff B., Grinnell BWGene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem2001; 276: 11199—11203.
25.
Esmon CTProtein C, protein S, and thrombomodulin. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. (eds) Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA : Lippincott Williams & Wilkins, 2001; 335—353.
26.
Heeb MJ, Gruber A., Griffin JHIdentification of divalent metal ion-dependent inhibition of activated protein C by alpha2macroglobulin and alpha2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem1991; 266: 17606—17612.
27.
Gruber A., Griffin JHDirect detection of activated protein C in blood from human subjects. Blood1992; 79: 2340—2348.
28.
Rezaie AR, Cooper ST, Church FC, Esmon CTProtein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex . J Biol Chem1995; 270: 25336—25339.
29.
Bourin MC, Lindahl U.Glycosaminoglycans and the regulation of blood coagulation. Biochem J1993; 289: 313—330.
30.
Rezaie ARVitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem2001; 276: 15567—15570.
31.
Bajzar L., Morser J., Nesheim M.TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin—thrombomodulin complex. J Biol Chem1996; 271: 16603—16608.
32.
Campbell W., Okada N., Okada H.Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev2001; 180: 162—167.
33.
Ikeguchi H., Maruyama S., Morita Y. et al. Effects of human soluble thrombomodulin on experimental glomerulonephritis . Kidney Int2002; 61: 490—501.
34.
Campbell WD, Lazoura E., Okada N., Okada H.Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbol Immunol2002; 46: 131—134.
35.
Xu J., Qu D., Esmon NL, Esmon CTMetalloproteolytic release of endothelial cell protein C receptor. J Biol Chem1999; 275: 6038—6044.
36.
Kurosawa S., Esmon CT, Stearns-Kurosawa DJThe soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CDIIb/CDI8. J Immunol2000; 165: 4697—4703.
37.
Taylor Jr FB , Stearns-Kurosawa DJ, Kurosawa S. et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis . Blood2000; 95: 1680—1686.
38.
Oganesyan V. , Oganesyan N., Terzyan S., Qu D., Dauter Z., Esmon N., Esmon CTThe crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem2002; 277: 24851—24854.
39.
Hong S., Scherer DC, Singh N. et al. Lipid antigen presentation in the immune system learned from CD1d knockout mice. Immunol Rev1999; 169: 31—44.
40.
Moody DB, Ulrichs T., Mhhlecker W. et al. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature2000; 404: 884—888.
41.
Busch C., Cancilla P., DeBault L., Goldsmith J., Owen W.Use of endothelium cultured on microcarriers as a model for the microcirculation . Lab Invest1982; 47: 498—504.
42.
Esmon CTThe roles of protein C and thrombomodulin in the regulation of blood coagulation . J Biol Chem1989; 264: 4743—4746.
43.
Esmon CT, Owen WGIdentification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA1981; 78: 2249—2252.
44.
Dreyfus M., Magny JF, Bridey F. et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med1991; 325: 1565—1568.
45.
Fukudome K. , Esmon CTIdentification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem1994; 269: 26486—26491.
46.
Conway EM, Rosenberg RDTumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol1988; 8: 5588—5592.
47.
Glaser CB, Morser J., Clarke JH et al. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. J Clin Invest1992; 90: 2565—2573.
48.
Takano S., Kimura S., Ohdama S., Aoki N.Plasma thrombomodulin in health and diseases. Blood1990; 76: 2024—2029.
49.
Fisher CJ, Yan SBProtein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med2000; 28: S49—S56.
50.
Faust SN, Levin M., Harrison OB et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med2001; 345: 408—416.
51.
Liaw Pcy, Ferrell GL, Loeb M., Foley R., Weitz JI, Esmon CTPatients with severe sepsis vary markedly in their ability to generate activated protein C [abstract]. Blood2001; 98: 445a.
52.
Hancock WW, Grey ST, Hau L. et al. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation1995 ; 60: 1525—1532.
53.
Yuksel M., Okajima K., Uchiba M., Horiuchi S., Okabe H.Activated protein C inhibits lipopolysaccharide-induced tumour necrosis factor-α production by inhibiting activation of both nuclear factor-κB and activator ptortein-1 in human monocytes. Thromb Haemost2002; 88: 267—273.
54.
Taoka Y., Okajima K., Uchiba M. et al. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes. J Neurosci1998; 18: 1393—1398.
55.
White B., Schmidt M., Murphy C. et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol2000; 110: 130—134.
56.
Coughlin SRThrombin receptor function and cardiovascular disease. Trends Cardiovasc Med1994; 4: 77—83.
57.
Comp PC, Jacocks RM, Ferrell GL, Esmon CTActivation of protein C in vivo. J Clin Invest1982; 70: 127—134.
58.
Beller-Todd BK, Archer LT, Hinshaw LBRecovery from endotoxin shock after extracorporeal perfusion without anticoagulation. Circ Shock1997; 6: 261—269.
59.
Taylor Jr FB , Chang A., Hinshaw LB, Esmon CT, Archer LT, Beller BKA model for thrombin protection against endotoxin . Thromb Res1984; 36: 177—185.
60.
Taylor Jr FB, Esmon CTTreatment of dysfunctional vascular endothelium using activated protein C . US Patent No.5,009,889, 1991.
61.
Taylor F., Chang A., Ferrell G. et al. C4b-binding protein exacerbates the host response to Escherichia coli. Blood1991; 78: 357—363.
62.
Murakami K. , Okajima K., Uchiba M. et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol1997; 272: L197—L202.
63.
Dreyfus M., Masterson M., David M. et al. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost1995; 21: 371—381.
64.
White B., Livingstone W., Murphy C., Hodgson A., Rafferty M., Smith OPAn open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood2000; 96: 3719—3724.
65.
Rivard GE, David M., Farrell C., Schwarz HPTreatment of purpura fulminans in meningococcemia with protein C concentrate . J Pediatr1995; 126: 646—652.
66.
Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med2001; 344: 699—709.
